Recent studies have highlighted the efficacy and manageable toxicity of combining Anlotinib with TQB2450, a novel PD‐L1 inhibitor, as a first‐line treatment for advanced ESCC. Here, CD274 is linked to esophageal squamous cell carcinoma.